Periodontitis therapy using autologous adipose-derived stromal cells: a double-blind randomized controlled clinical trial in an aged canine model.
Monsarrat P., Laurencin-Dalicieux S., Jourdan G., Blasco-Baque V., Bourdens M., Bouhsira E.
Randomized Controlled Trial, published in Cytotherapy (2024) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- Cytotherapy (2024)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42212991
- DOI
- 10.1016/j.jcyt.2024.10.012
- Citations
- 1
Abstract (original English)
Background aims The aim of this randomized double-blind trial was to assess the biosafety and efficacy of cell therapy by adipose-derived stromal cells (ASCs) in a suitable hydrogel biomaterial to improve clinical and biological outcomes in a canine model of spontaneous periodontitis. Methods A total of 16 elderly beagle dogs with spontaneous periodontitis were included in a double-blind split-mouth design. After non-surgical periodontal treatment, mandibular lesions were randomly grafted with a platelet lysate-based hydrogel with or without autologous ASCs. Clinical and biological examination assessed the severity of periodontal tissue loss, inflammatory activity and subgingival microbiota initially and at 45 days and 120 days (four dogs) after grafting. Histological analyses were also carried out at 120 days. RNA sequencing was performed to identify the ASC expression fingerprint of clinical improvement. Results The adjusted mean difference (95% confidence interval) highlighted a significant improvement in tissue gain and inflammation reduction at 120 days (periodontal pocket depth, -1.24 mm [-1.64, -0.85], clinical attachment level, -1.16 mm [-1.80, -0.53], Gingival Index, -0.37 [-0.52, -0.22]) together with a decrease in periopathogenic subgingival microbiota. Microscopic analysis demonstrated more stabilized periodontium in ASC-grafted sites than controls. RNA sequencing p
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.